Achalasia of the esophagus - Contemporary review of etiopathogenesis and available treatment;Achalazie jícnu - Aktuální přehled etiopatogeneze a dostupné terapie

Ceska a Slovenska Gastroenterologie a Hepatologie

Volumn 60, Issue 3, 2006, Pages 135-139

  Kroupa, Radek ^a   Hep, Aleš ^a   Dolina, Jiří ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Achalasia; Autoimmunity; Botulotoxin; Heller's myotomy; Pneumatic dilatation

Indexed keywords

CARDIOESOPHAGOMYOTOMY; ESOPHAGUS ACHALASIA; HUMAN; PATHOGENESIS; REVIEW; UPPER ESOPHAGUS SPHINCTER;

EID: 33746310973     PISSN: 1213323X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Gockel I, Eckardt VF, Schmitt T, et al. Pseudoachalasia: a case series and analysis of the literature. Scand J Gastroenterol 2005; 40(4): 378-385.
2. Richter J. Oesophageal motility disorders. Lancet 2001; 358: 823-828.
3. Crist J, Gidda JS, Goyal RK. Intramural mechanism of esophageal peristalsis: roles of cholinergic and non cholninergic nerves. Proc Natl Acad Sci USA 1984; 81: 3595-3599.
4. Goldblum JR, Rice TW, Richter JE. Histopatologic features in esophagomyotomy specimens from patients with achalasia. Gastroenterology 1996; 111: 648-654.
5. Mearin F, Mourelle M, Guarner F, et al. Patients with achalasia lack nitric oxide synthase in the gastro-oesophageal junction. Eur J Clin Invest 1993; 23: 724-728.
6. Jones DB, Mayberry JF, Rhodes J, et al. Preliminary report of an association between measles virus and achalasia. J Clin Pathol 1983; 36: 655-657.
7. Robertson CS, Martin BA, Atkinson M. Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut 1993; 34: 299-302.
8. Niwamoto H, Okamoto E, Fujimota J, et al. Are human herpes viruses or measles associated with esophageal achalasia? Dig Dis Sci 1995; 40: 859-864.
9. Birgisson S, Galinsky MS, Goldblum JR, et al. Achalasia is not associates with measles or known herpes and human papilloma viruses. Dig Dis Sci 1997; 42: 300-306.
10. Storch WB, Eckardt VF, Wienbeck M, et al. Autoantibodies to Auerbach's plexus in achalasia. Cell Mol Biol 1995; 41: 1033-1038.
11. Verne GN, Salluslio JE, Eaker EY. Anti-myenteric neuronal antibodies in patients with achalasia. A prospective study. Dig Dis Sci 1997; 42: 307-313.
12. Spechler SJ. AGA technical review on treatment of patients with dysfagie caused by benign disorders of the distal esophagus. Gastroenterology 1999; 117: 299-302.
13. Moses PL, Ellis LM, Anees MR, et al. Antineuronalantibodies in idiopathic achalasia and gastro-esophageal reflux disease. Gut 2003; 52: 629-636.
14. Bruley des Varannes S, Chevalier J, Pimont S, et al. The serum of achalasia patients alters neurochemical coding in the myenteric plexus and NO-mediated motor response in normal human fundus. Gut 2006; 55(3): 319-329.
15. Clark SB, Rice TW, Tubbs RR, et al. The nature of the myenteric infiltrate in achalasia: an immunohistochemical analysis. Am J Surg Pathol 2000; 24: 1153-1158.
16. Ruiz de Leon A, Mendoza J, Sevilla-Mantilla C, et al. Myenteric antiplexux antibodies and class II HLA in achalasia. Dig Die Sci 2002; 47: 15-19.
17. Brooks BP, Kleta R, Stuart C, et al. Genotypic heterogeneity and clinical phenotype in triple A syndrome: a review of the NIH experience 2000-2005. Clin Genet 2005; 68(3): 215-221.
18. Di Nardo G, Tullio-Pelet A, Annese V, et al. Idiopathic achalasia is not allelic to alacrima achalasia adrenal insufficiency syndrome at the ALADIN locus. Dig Liver Dis 2005; 37(5): 312-315.
19. De Giorgio R, Guerrini S, Barbara G, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004; 126: 1872-1883.
20. Park W, Vaezi MF. Etiology and pathogenesis of achalasia: the current understanding. Am J Gastroenterol 2005; 100: 1404-1414.
21. Boeckxstaens GE, Jonge WD, van den Wijngaard RM, et al. Achalasia: from new insights in pathophysiology to treatment. J Pediatr Gastroenterol Nutr 2005; 41(Suppl. 1): S36.
22. Micci MA, Learish RD, Li H, et al. Neural stem cells express RET, produce nitric oxide, and survive transplantation in the gastrointestinal tract. Gastroenterology 2001; 121: 757-766.
23. Pandolfino JE, Kahrilas PJ, American Gastroenterological Association medical position statement: clinical use of esophageal manometry. Gastroenterology 2005; 128(1): 207-208.
24. Vaezi MF, Richter JE. Diagnosis and management of achalasia. Practice guidelines. Am J Gastroenterol 1999; 94: 3406-3412.
25. Tack J. Medical treatment of achalasia. In: Gouma DJ, et al. New developments in the management of benign GI disorders 2004. Paris: John Libbey Eurotext 2004: 13-23.
26. Pasricha PJ, Ravich WJ, Hendrix TR, et al. Treatment of achalasia with intrasphincteric injection of botulinum toxin: a pilot trial. Ann Intern Med 1994; 121: 590-591.
27. Annese V, Bassoti G, Cocia G, et al. Comparison of two different formulations of botulinum toxin A for treatment of esophageal achalasia. Aliment Pharmacol Ther 1999; 13: 1347-1350.
28. Gui D, Rossi S, Runfola M, et al. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther 2003; 18: 1-16.
29. Pasricha PJ, Rai R, Ravich WJ, et al. Botulinum toxin for achalasia: long term outcome and predictors of response. Gastroenterology 1996; 110: 1410-1415.
30. Annese V, Basciani M, Borrelli O, et al. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of achalasia. Muscle Nerve 1998; 21: 1540-1542.
31. Martinek J, Spicak J. A modified method of botulinum toxin injection in patients with achalasia: a pilot trial. Endoscopy 2003; 35(10): 841-844.
32. Zarate N, Mearin F, Baldovino F, et al. Achalasia treatment in the elderly: is botulinum toxin injection the best option? Eur J Gastroenterology and Hepatology 2002; 14: 285-290.
33. Neubrand M, Scheurlen C, Schepke M, et al. Long term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 2002; 34(7): 519-523.
34. Vela MF, Richter JE, Wachsberger D, et al. Complexities of managing achalasia at a tertiary referral center: use of pneumatic dilatation, Heller myotomy, and botulinum toxin injection. Am J Gastroenterol 2004; 99(6): 1029-1036.
35. Allescher HD, Storr M, Seige M, et al. Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-Up. Endoscopy 2001; 33(12): 1007-1017.
36. Muehldorfer SM, Schneider TH, Hochberger J, et al. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus baloon dilatation. Endoscopy 1999; 31(7): 517-521.
37. Vaezi MF, Richter JE, Wilcox CM, et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomized trial. Gut 1999; 44: 231-239.
38. Chan KC, Wong SK, Lee DW, et al. Short-term and long-term results of endoscopic balloon dilation for achalasia: 12 years' experience. Endoscopy 2004; 36(8): 690-694.
39. Kadakia SC, Wong RH. Graded pneumatic dilatation using Rigiflex achalasia dilators in patients with primary esophageal achalasia Am J Gastroenterol 1993; 88: 34-38.
40. Ghoshal UC, Kumar DM, Saraswar VA, et al. Long term follow up after pneumatic dilatation for achalasia cardia: factors associated with treatment failure and recurrence. Am J Gastroenterol 2004; 99: 2304-2310.
41. Hep A, Dolina J, Plottová Z, et al. Is the complex therapy of achalasia by application of botulotoxin in combination with balloon dilatation a prospective approach? Bratisl lek Listy 2000; 101: 433-437.
42. Mikaeli J, Bishehsari F, Montazeri G, et al. Efficacy of botulinum toxin injection before pneumatic dilatation in patients with idiopathic achalasia. Dis Esophagus 2004; 99: 213-217.
43. Vaezi MF, Baker ME, Richter JE. Assessment of esophageal emptying post-pneumatic dilatation: use of timed-barium esophagogram. Am J Gastroenterol 1999; 94: 1802-1807.
44. Zaninotto G, Annese V, Costantini M, et al. Randomized controlled trial of botulinum toxin versus laparoscopic heller myotomy for esophageal achalasia. Ann Surgery 2004; 239(3): 364-370.
45. Chen LQ, Chughtai T, Sideris L, et al. Long-term effects of myotomy and partial fundoplication for esophageal achalasia. Dis Esophagus 2002; 15(2): 171-179.
46. Lhi JF, Zhang J, Tian ZQ, et al. Long-term outcome of esophageal myotomy for achalasia. World J Gastroenterol 2004; 10(2): 287-291.
47. Nguen NQ, Holloway RH. Recent developments in esophageal motor disorders. Current Opinion in Gastroenterology 2005; 21: 478-484.
48. Zaninotto G, Costantini M, Portale G, et al. Etiology, diagnosis, and treatment of failures after laparoscopic Heller myotomy for achalasia. Ann Surg 2002; 235(2): 186-192.
49. Lovecek M, Gryga A, Herman J, et al. Peroperační diagnostické melody při operaci achalazie jícnu. První zkušenosti. Rozhl Chir 2003; 82(11): 566-569.
50. Richter JE. Comparison and cost analysis of different treatment strategies in achalasia. Gastrointest Endosc Clin N Am 2001; 11: 359-369.
51. Arain MA, Peters JH, Tamhankar AP, et al. Preoperative lower esophageal sphincter pressure affects outcome of laparoscopic esophageal myotomy for achalasia. J Gastrointest Surg 2004; 8(3): 328-334.
52. Bloomston M, Fraiji E, Boyce jr HW, et al. Preoperative intervention does not affect esophageal muscle histology or patient outcomes in patients undergoing laparoscopic Heller myotomy. J Gastrointestinal Surgery 2003; 7(2): 181-188.
53. Horgan S, Hudda K, Eubanks I, et al. Does botulinum toxin injection make esophagomyotomy a more difficult operation? Surg Endosc 1999; 13: 576-579.
54. Deb S, Deschamps C, Allen MS, et al. Laparoscopic esophageal myotomy for achalasia: factors affecting functional results. Ann Thorac Surg 2005; 80(4): 1191-1194.
55. Portale G, Costantini M, Rizzetto C, et al. Long-term outcome of laparoscopic heller-dor surgery for esophageal achalasia: possible detrimental role of previous endoscopie treatment. J Gastrointest Surg 2005; 9(9): 1332-1339.
56. Rosemurgy A, Villadolid D, Thometz D, et al. Laparoscopic Heller myotomy provides durable relief from achalasia and salvages failures after botox or dilation. Ann Surgery 2005; 241(5): 725-733.
57. Brucher BL, Stein HJ, Bartels H, et al. Achalasia and esophageal cancer: incidence, prevalence, prognosis. World J Surg 2001; 25: 745-779.
58. Shaheen NJ. What is the best management strategy for achalasia? Comment. Gastroenterology 2004; 127(6): 1850-1852.
59. Urbach DR, Hansen PD, Khajanchee YS, et al. A decision analysis of the optimal initial approach to achalasia: laparoscopic Heller myotomy with partial fundoplication, thoracoscopic Heller myotomy, pneumatic dilatation, or botulinum toxin injection. J Gastrointest Surg 2001; 5(2): 192-205.
60. Hep A, Kroupa R, Matyasova Z, et al. Combined treatment - botulinum toxin and pneumatic dilatation in patients with achalasia - long term results Dis Esophagus 2004; 17(Suppl. 1): A21.
61. Aujeský R, Neoral Č, Král V, et al. Současné možnosti léčby achalazie jícnu. Rozhl Chir 2000; 79(3): 99-101.